Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Medulloblastoma in adults

Medulloblastoma in adults Strahlenther Onkol (2018) 194:225–234 https://doi.org/10.1007/s00066-017-1235-5 ORIGINAL ARTICLE A retrospective single institution analysis 1 1 1 1,2 3,4,5 Indrawati Hadi · Olarn Roengvoraphoj · Maximilian Niyazi · Falk Roeder · Ulrich Schüller · 1,6 1 Claus Belka · Silke Birgit Nachbichler Received: 31 July 2017 / Accepted: 26 October 2017 / Published online: 16 November 2017 © Springer-Verlag GmbH Deutschland 2017 Abstract tients. The most common side effects were hematologi- Purpose Adult medulloblastoma is a rare disease treated cal toxicities. Median overall survival (OS) has not been according to the current pediatric treatment guidelines. This reached after a median follow-up of 92 months. Estimated retrospective analysis investigated the clinical outcomes and 5- and 10-year OS was 89 and 80%, respectively. Estimated prognostic factors of adult medulloblastoma patients, who 5- and 10-year progression-free survival (PFS) was 89 and received multimodal therapy at our institution. 81%, respectively. In univariate analysis, a shorter interval Methods Treatment charts of all patients over the age of between tumor resection and end of irradiation was signif- 15 years of age with de novo medulloblastoma, who had icantly associated with improved OS and PFS, anaplastic been treated at our institution between 2001 and 2014, histology with worse http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Strahlentherapie und Onkologie Springer Journals

Loading next page...
 
/lp/springer_journal/medulloblastoma-in-adults-PZ0M16EUdl

References (27)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag GmbH Deutschland
Subject
Medicine & Public Health; Radiotherapy; Oncology
ISSN
0179-7158
eISSN
1439-099X
DOI
10.1007/s00066-017-1235-5
pmid
29147840
Publisher site
See Article on Publisher Site

Abstract

Strahlenther Onkol (2018) 194:225–234 https://doi.org/10.1007/s00066-017-1235-5 ORIGINAL ARTICLE A retrospective single institution analysis 1 1 1 1,2 3,4,5 Indrawati Hadi · Olarn Roengvoraphoj · Maximilian Niyazi · Falk Roeder · Ulrich Schüller · 1,6 1 Claus Belka · Silke Birgit Nachbichler Received: 31 July 2017 / Accepted: 26 October 2017 / Published online: 16 November 2017 © Springer-Verlag GmbH Deutschland 2017 Abstract tients. The most common side effects were hematologi- Purpose Adult medulloblastoma is a rare disease treated cal toxicities. Median overall survival (OS) has not been according to the current pediatric treatment guidelines. This reached after a median follow-up of 92 months. Estimated retrospective analysis investigated the clinical outcomes and 5- and 10-year OS was 89 and 80%, respectively. Estimated prognostic factors of adult medulloblastoma patients, who 5- and 10-year progression-free survival (PFS) was 89 and received multimodal therapy at our institution. 81%, respectively. In univariate analysis, a shorter interval Methods Treatment charts of all patients over the age of between tumor resection and end of irradiation was signif- 15 years of age with de novo medulloblastoma, who had icantly associated with improved OS and PFS, anaplastic been treated at our institution between 2001 and 2014, histology with worse

Journal

Strahlentherapie und OnkologieSpringer Journals

Published: Nov 16, 2017

There are no references for this article.